HKD 3.2
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 25.06 Million CNY | -108.72% |
2022 | 619.32 Million CNY | 10.0% |
2021 | 524.28 Million CNY | 48.11% |
2020 | 382.01 Million CNY | 1678.09% |
2019 | 35.32 Million HKD | 187.13% |
2018 | 1.68 Million HKD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -48.52 Million HKD | 14.92% |
2024 Q2 | -48.1 Million HKD | 0.15% |
2023 Q2 | 21.07 Million HKD | -5.52% |
2023 Q3 | -56.7 Million HKD | -369.02% |
2023 FY | - CNY | -108.72% |
2023 Q4 | -58.16 Million HKD | -2.57% |
2023 Q1 | 22.3 Million HKD | -81.44% |
2022 Q3 | 117.2 Million HKD | -73.37% |
2022 FY | - CNY | 10.0% |
2022 Q4 | 120.22 Million HKD | 2.58% |
2022 Q2 | 440.05 Million HKD | 0.0% |
2021 FY | - CNY | 48.11% |
2020 FY | - CNY | 1678.09% |
2019 FY | - HKD | 187.13% |
2018 FY | - HKD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Life Healthcare Group Limited | 27.68 Million HKD | 9.459% |
China Biotech Services Holdings Limited | -73.45 Million HKD | 134.128% |